Sentia Medical Sciences Inc. Awarded Approximately $1.8 million Phase II Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
May 22, 2019
Sentia Medical Sciences Inc. Appoints Dr. Yvette Taché as Chair of the Scientific Advisory Board and Announces Award of a Phase 1 Small Business Innovation Research (SBIR) Grant to Develop Astressins for the Treatment of Irritable Bowel Syndrome (IBS)
June 12, 2018
Sentia Medical Sciences Inc. Announces the Launch of a New Initiative in Stress-related Disorders Targeting Gastrointestinal and Endocrine Diseases
November 17, 2017